BLOG
Se vacciner à nouveau contre le COVID, le choix de la cigale ou de la fourmi ?
Un deuxième booster anti-COVID après le premier est recommandé pour les personnes à risque. Depuis peu les autres personnes éligibles à ce rappel doivent payer de leur poche en Suisse.
La taxe de 1% sur l’innovation continuera d’être payée par les PME. Comment corriger l’erreur ?
Une victoire de la gauche basée sur le mépris des PME et des start-ups qui investissent dans l’innovation et leur croissance
Pourquoi taxer l’innovation et la croissance à 1% ?
Le 13 février nous votons sur la suppression du droit de timbre sur l’émission de capital propre.
Quand aurons-NOUS un vaccin contre les variants COVID-19 ?
Après une promesse en juin par le CEO de Pfizer à la conférence du G7, il y a enfin des nouvelles avec des essais cliniques en cours et un article dans la revue scientifique Nature.
Discussion hallucinante avec un couple sceptique sur le COVID
Après plusieurs posts sur le COVID, je ne résiste pas à relater une discussion surréaliste dans le tram avec un jeune couple ne portant pas le masque.
NEWS
Mablink Bioscience Enters an Agreement to be Acquired by Lilly
Mablink today announced an agreement to be acquired by Eli Lilly and Company.
NETRIS Pharma announces data published in two Nature papers confirming netrin-1 blockade as significant clinical strategy in oncology
NETRIS Pharma publishes two back-to-back papers in Nature journal on NP137 being effective in reducing tumor growth and inhibiting tumor epithelial-to-mesenchymal transition (EMT).
Mablink Bioscience appoints Pejvack Motlagh, M.D., as Chief Medical Officer
Mablink appoints Pejvack Motlagh, M.D., as CMO who will serve on the Executive Management Team and report directly to Mablink’s CEO.
TheraPPI to present at Event BioValley Basel – Business Angel Chapter
TheraPPI’s CEO will present at BioValley Basel on 19 June 2023.
TheraPPI to present at TechTour in Paris
TheraPPI’s CEO will present at TechTour in Paris on 2nd June 2023.
TheraPPI among the Finalists of the 2023 >>venture>>
TheraPPI Bioscience is finalist of 2023 >>venture>>, a highly competite startup challenge.
NETRIS Pharma Doses First Patient in Pancreatic Cancer Clinical Study with NP137
NETRIS Pharma initiates Lap-NET1, a multicenter, prospective, single arm, proof-of-concept trial of NP137, in combination with mFOLFIRINOX in first line patients with locally advanced pancreatic ductal adenocarcinoma.
Mablink Bioscience to Present Promising Preclinical Data for Lead ADC Candidate MBK-103 at the AACR
Mablink will present preclinical efficacy and safety data on its lead program, MBK-103, at the AACR Meeting 2023 on April 17, 2023, in Orlando, Florida.
NETRIS Pharma Doses First Patient in Hepatocellular Carcinoma (HCC) Clinical Study with NP137
NETRIS Pharma initiates Liver-NET1, a multicenter, prospective, single arm, proof-of-concept trial of NP137, in combination with atezolizumab-bevacizumab in first line patients with advanced hepatocellular carcinoma.
A new review on the history and future of ADC payloads published by Mablink’s scientists
Mablink announces the publication of a review article on payload and ADC in Journal of Hematology & Oncology.
NETRIS Pharma led consortium awarded €1.2 million Eurostar grant to explore netrin-1 targeted therapeutics
A consortium of leading European academic institutions and biotech companies have been awarded a €1.2 million Eurostar grant for ACTaNet project to generate preclinical PoC data with NETRIS’s NP137 for treating arthritis and metastatic bone cancer related chronic pain.
France 2030: Mablink is awarded 1.8 million euros in the i-Nov innovation competition
Mablink is the winner of the 9th wave of the i-Nov innovation competition organized by Bpifrance and receives a grant of 1.8 million euros.